Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17 –30 months
ConclusionApproximately 55% of treatment resistant or difficult to treat CM patients who trialled erenumab in our clinics reported a subjective benefit and were still on treatment after 17 –30 months.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: Amitriptyline | Brain | Chronic Pain | Clinical Trials | Disability | Genetics | Headache | Inderal | Migraine | Neurology | Pain | Study | Topamax